GNI Group Ltd. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
3,551
4,951
3,728
3,094
5,086
5,963
Total Accounts Receivable
23
121
71
277
744
828
Inventories
122
220
175
261
638
612
Other Current Assets
76
33
41
53
84
160
Total Current Assets
3,773
5,326
4,016
3,684
6,552
7,562
Net Property, Plant & Equipment
247
565
743
617
1,461
2,056
Total Investments and Advances
-
6
751
753
346
317
Long-Term Note Receivable
-
32
41
44
37
30
Intangible Assets
724
433
426
365
7,047
6,707
Other Assets
8
412
390
348
421
411
Total Assets
4,752
6,774
6,386
5,819
15,879
17,101
ST Debt & Current Portion LT Debt
92
242
209
190
843
Accounts Payable
38
57
50
60
46
Income Tax Payable
81
-
17
67
93
Other Current Liabilities
98
204
340
445
506
Total Current Liabilities
308
503
617
763
1,487
Long-Term Debt
312
269
469
488
479
Deferred Taxes
-
-
18
10
377
Other Liabilities
159
204
172
35
38
Total Liabilities
779
976
1,258
1,286
2,397
Common Equity (Total)
2,833
4,438
3,835
3,261
11,719
Total Shareholders' Equity
2,833
4,438
3,835
3,261
11,719
Total Equity
3,973
5,798
5,128
4,533
13,482
Liabilities & Shareholders' Equity
4,752
6,774
6,386
5,819
15,879
Accumulated Minority Interest
1,140
1,360
1,292
1,272
1,763

About GNI Group

View Profile
Address
Nihonbashi Honcho YS Bldg., 3/F
Tokyo Tokyo 103
Japan
Employees -
Website http://www.gnipharma.com
Updated 07/08/2019
GNI Group Ltd. engages in the development, research, manufacture, and sales of pharmaceutical drugs and traditional Chinese medicines. It operates through Japan and China segments. The Japan segment deals with licensing, preclinical studies, clinical trials, and sales.